ClinicalTrials.gg
RecruitingNCT06764719Updated Oct 27, 2026

Cryopreserved Hair Follicles for Disease and Cell Replacement

An observational study in Diabetes Mellitus, Sport Injury and Injury Traumatic, sponsored by Acorn Biolabs Inc.. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Acorn Biolabs Inc. · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 493 studies in Diabetes Mellitus with a site in Canada — 39 open to participants now, 55 under way, 5 of them phase 3. Diabetes Mellitus · Canada.

Planned enrollment
44th of 92
100 · median 100
Started
2025
with 7 others
Observational
92 of 493
14 open now
Primary completion
2027-06
later than 31 of 54 live
Registered
471st of 493
by date

Among the 493 studies in Diabetes Mellitus with a site in Canada, this one is the 44th largest by planned enrollment of the 92 observational ones that give a count, is one of 8 that started in 2025, is one of 92 observational ones, reaches primary completion later than 31 of the 54 other live ones, and was the 471st registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

39 of the 493 studies in Diabetes Mellitus with a site in Canada are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 493 studies in Diabetes Mellitus with a site in Canada, or all of them as a file.
02

Study summary

To explore the application of cells expanded from plucked hair follicles after collection, transport, and cryopreservation, in disease modeling and cell-based therapies.

Read the detailed description

Hair Follicles collected and transported in Acorn's proprietary transport media can serve has therapeutic starting materials for future cell-based therapeutics. This study is to characterize primary cell outgrowth, functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s) as well as evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s).

03

Conditions studied

  • Diabetes Mellitus
  • Sport Injury
  • Injury Traumatic

Keywords

  • Hair follicles
  • stem cells
  • pluripotent
  • cell differentiation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy population, aged 18-80, without scalp or hair disorders, chronic illnesses that may impact scalp health or wound healing, and not on immunosuppressants, steroids, or medications that cause hair loss.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender: Male or Female.
  • Age: ≥18 and ≤80 years.
  • Language proficiency: Able to read and understand English.
  • : Willing to provide written, informed consent to participate in all study activities.

Exclusion criteria

Exclusion Criteria:

  • Scalp/Hair Disorders: Subjects diagnosed with active scalp infections or inflammatory skin conditions.
  • Systemic Conditions: Subjects with chronic illnesses, such as diseases or diabetes, that may impact scalp health or wound healing.
  • Medications: Subjects on , , or other medications associated with hair loss.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hair Follicle Donors

    Healthy individuals, aged 18-80, who will have hair follicles collected

06

What researchers measure

Primary outcomes

  1. Characterize primary cellular outgrowth(s)

    10 hair follicles will be placed in a tissue culture plate per participants. Over the course of 30 days, the outgrowth percentage (the number of outgrowths present out of 10 will be monitored and the confluency (percent of cells present in relation to surface area) will be noted for each participant.

    Time frame: 30 days

  2. Evaluate functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s)

    1 million keratinocytes will be taken for reprogramming for each participant. The number of iPS colonies observed on day 21 will be noted, resulting in a reprogramming efficiency score.

    Time frame: 21 days

  3. Evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s)

    iPS cell lines which have been confirmed to be pluripotent will be differentiated into pancreatic progenitor cells and hematopoietic stem cells. The cells will be analyzed using FLOW cytometry and the percentage of double positive cells will be noted for each participant. This will be repeated for multiple pathways such as the hematopoietic and endothelial lineage(s).

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Acorn Biolabs
    Toronto, Quebec M5R 0C7, Canada
    Recruiting
    • Drew Taylor, MSc, PhD · Contactinfo@acorn.me · 226-929-8476
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jan 2026 → Jun 2027 and completion Mar 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 8, 2025
StartActual
Jan 6, 2025
Primary completionEst.
Jun 30, 2027was Jan 2026
CompletionEst.
Dec 31, 2027was Mar 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2026→Jun 30, 2027
Oct 27, 2026
Study completion
Mar 2026→Dec 31, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Jan 2026→Jun 30, 2027
    Study completion Mar 2026→Dec 31, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06764719
Lead sponsor
Acorn Biolabs Inc.
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Jan 6, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Drew Taylor, MSc, PhD
Contact
info@acorn.me
226-929-8476

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion